What Genesis Regenerative does

Genesis Regenerative is a privately held US LLC (formed 2023, headquartered in Clearwater, FL with operational offices in Texas) that develops and distributes regenerative medicine products to licensed clinicians. The company's flagship product is the Regenerative Protein Array (RPA), an acellular formulation derived from screened placental tissue that delivers over 300 proteins, cytokines, growth factors, and miRNA, compared with approximately 40 active factors in conventional platelet-rich plasma (PRP) therapies. RPA is manufactured in an FDA-registered facility using a proprietary bioreactor process that harvests components from all three placental germ layers (endo/ecto/mesoderm), positioning the product as a non-biologic alternative to cell-based regenerative treatments.

The company's second product, Push Patch, is a needle-free transdermal peptide delivery system that uses iontophoresis (low-voltage electrodes) to deliver therapeutic molecules through the skin with a 12-hour time-release profile, eliminating the need for injections or IV therapy. Genesis Regenerative sells and licenses these products to clinical practices via a B2B partnership model, providing clinicians with clinical protocols, regulatory support, lab testing, referral marketing assistance, and a secure clinician portal (registry, forum, case study videos, patient financing).

The go-to-market strategy is partnership-driven US clinic expansion. From October 2025 through March 2026, the company rapidly onboarded clinical partners across Florida, Nebraska, Michigan, California, Georgia, Pennsylvania, Hawaii, Nevada, Illinois, and New York, including concierge clinic deployments and specialty practices in podiatry, pain management, functional medicine, and regenerative orthopedics. The Medical Directors Advisory Board (Drs. Jacobson, Johnson, Bregman, Korth) and laboratory leadership (Holly Hewitt, CTBS, 31 years in tissue transplantation) provide clinical and regulatory credibility. Pricing is not publicly disclosed, and the company has not announced any institutional funding rounds, acquisitions, or revenue figures.

Name

Genesis Regenerative

Legal name

Genesis Regenerative, LLC

Website

https://genesisregenerative.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

Genesis Regenerative is a US regenerative medicine company that distributes its placental-tissue-derived Regenerative Protein Array (RPA) and needle-free Push Patch peptide therapy to licensed clinicians via a B2B clinic partnership model, targeting joint, soft tissue, neurological, and chronic pain conditions.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Biologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL)

akta.pro secondary industry

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

Keywords

• Regenerative medicine
• Protein array therapy
• Biologic treatments
• Needle-free delivery
• Placental tissue therapy

Headquarters

HQ city

Clearwater

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Core offering

Genesis Regenerative develops and distributes two core therapeutic products to licensed clinicians: the Regenerative Protein Array (RPA), an acellular biologic derived from screened placental tissue containing over 300 proteins, cytokines, growth factors, and miRNA; and Push Patch, a needle-free peptide delivery system using iontophoresis technology with 12-hour time-release. The company supports clinicians with clinical, regulatory, administrative, and educational resources to deliver regenerative therapies for joint, soft tissue, neuro-cognitive, podiatric, and peptide-related conditions.

Product overview

Genesis Regenerative offers two core therapeutic products: the Regenerative Protein Array (RPA) as the primary platform product, and Push Patch as a complementary needle-free delivery technology. RPA is an acellular protein formulation derived from placental tissue, while Push Patch enables transdermal peptide delivery through iontophoresis. These products are positioned as next-generation regenerative therapies designed for use by licensed clinicians across multiple medical specialties to address various chronic and acute health conditions.

Differentiator

Problem solved

Functional benefit

Brands

• Regenerative Protein Array (RPA): The company's primary therapeutic product - an acellular formulation delivering over 300 proteins, cytokines, and growth factors derived from placental tissue.
• Push Patch

Products and services

• Regenerative Protein Array (RPA) An acellular, non-biologic regenerative therapy containing over 300 proteins, cytokines, growth factors, and miRNA derived from screened placental tissue. Produced in an FDA-registered facility using a proprietary bioreactor process that harvests components from all three layers of the placenta (endo/ecto/mesoderm). The product modifies the surrounding cellular environment through biological signals rather than direct cell transformation. Designed for use by licensed clinicians across multiple medical specialties to address joint, soft tissue, musculoskeletal, neuro-cognitive, podiatric, and other chronic and acute conditions.
• Push Patch Needle-Free Peptide Therapy A needle-free peptide delivery system using iontophoresis technology via low voltage electrodes in a patch to deliver therapeutic molecules and peptides through the skin into the bloodstream. Features 12-hour time-release technology providing sustained bioavailability without daily injections or weekly IV treatments. Designed for use by licensed clinicians offering peptide and regenerative therapies to patients seeking non-invasive treatment options.

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves6 records

Expansion highlights5 records

Direct peers

• Organogenesis: Organogenesis (NASDAQ: ORGO) markets regenerative biologics including Apligraf, Dermagraft, and PuraPly for wound healing and surgical applications. It is directly comparable to Genesis in selling tissue-derived regenerative products to clinicians for chronic condition management.
• Surgenex: Surgenex produces placental tissue allografts (e.g., SurForce, SurGraft) sold to orthopedic, wound care, and pain management physicians. It operates in the same regenerative biologic space as Genesis Regenerative.
• MIMEDX: MIMEDX develops and commercializes placental tissue-based products (EpiFix, AmnioFix, etc.) for wound care and musculoskeletal applications. It is the most direct competitor to Genesis Regenerative's RPA, offering purified tissue-derived biologics to clinicians through a similar specialty distribution model.
• Skye Biologics: Skye Biologics offers a portfolio of dehydrated amniotic membrane and placental tissue allografts for wound, orthopedic, and pain management applications. Its distribution model through specialty physician offices mirrors Genesis Regenerative's clinic-partnership go-to-market approach.
• StimLabs: StimLabs produces placental tissue allografts and regenerative biologics (e.g., Stimulen, AmnioMatrix) for wound care and orthopedic use. Like Genesis, it sells processed placental tissue-derived products to specialist clinicians across multiple U.S. states.
• Amniox Medical: Amniox Medical (a TissueTech subsidiary) markets CLARIX and NEOX placental tissue products for surgical, orthopedic, and pain management indications. It is a direct competitor in the regenerative protein/biologic category targeted by Genesis's RPA.

Broad incumbents

• Arthrex: Arthrex is a large privately-held orthopedic medical device company offering autologous conditioned plasma (ACP) systems, bone graft substitutes, and regenerative biologics. It is a broad incumbent that competes with Genesis for orthopedic clinician relationships at much greater scale.
• Vericel: Vericel (NASDAQ: VCEL) markets MACI (autologous chondrocyte implant) and Epicel for cartilage and burn repair. While it specializes in cell therapies rather than acellular protein arrays, it competes in the orthopedic regenerative medicine category Genesis targets.
• Integra LifeSciences: Integra LifeSciences (NASDAQ: IART) offers regenerative technologies including dermal matrices, wound care, and orthopedic tissue products. It overlaps with Genesis's regenerative biologic positioning as a much larger diversified medical device incumbent.

Emerging players

• BioLab Sciences: BioLab Sciences develops regenerative wound and tissue products including fluidflow and MemoVet amniotic membrane allografts. It is a smaller emerging player overlapping with Genesis's placental tissue-derived biologic positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genesis Regenerative